$6.385
-0.536 (-8.39%)At close
NVNO News
NVNO Events
enVVeno Medical Trading Resumes
enVVeno Medical trading resumes
enVVeno Medical Trading Halted Due to Volatility
enVVeno Medical trading halted, volatility trading pause
enVVeno Medical Files $100M Mixed Securities Shelf
enVVeno Medical files $100M mixed securities shelf
Company Reports Q2 Cash Burn of $3.4M
Cash burn for the second quarter was $3.4M, consistent with the Company's projected cash burn rate of approximately $3M to $4M per quarter. The Company anticipates that its cash burn rate will likely increase to between $4M and $5M per quarter in the second half of 2026 as the TAVVE study begins enrolling patients.
enVVeno Approved to Proceed with enVVe Pivotal Study
"The second quarter represented a defining milestone for enVVeno, as we got the approval to move forward with the pivotal study for enVVe, our non-surgical replacement venous valve. enVVe has the potential to completely change the treatment trajectory for the 3 million U.S. patients in the U.S. that suffer from severe, deep venous CVI and have no effective treatment options," commented Rob Berman, CEO. "As we enter the second half of 2026, our focus is squarely on executing the TAVVE pivotal study, getting our clinical sites up and running, and treating the first patients."
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.